Back to Search
Start Over
Assessments of the Value of New Interventions Should Include Health Equity Impact
- Source :
- PharmacoEconomics, vol 40, iss 5
- Publication Year :
- 2022
-
Abstract
- A formal evaluation of the health equity impact of a new intervention is hardly ever performed as part of a health technology assessment to understand its value. This should change, in our view. An evidence-based quantitative assessment of the health equity impact can help decision makers develop coverage policies, programme designs, and quality initiatives focused on optimizing both total health and health equity given the treatment options available. We outline the conceptual basis of how a new intervention can impact health equity and adopt distributional cost-effectiveness analysis based on decision-analytic models to assess this quantitatively, using a newly US FDA-approved drug for Alzheimer's disease (aducanumab) as an example. We argue that gaps in the evidence base for the new intervention, for example, due to limited clinical research participation among racial and ethnic minority groups, do not preclude such an evaluation. Understanding these uncertainties has implications for fair pricing, decision making, and future research. If we are serious about population-level decision making that not only is focused on improving total health but also aims to improve health equity, we should consider routinely assessing the health equity impact of new interventions.
- Subjects :
- Pharmacology
Aging
Comparative Effectiveness Research
Technology Assessment, Biomedical
Biomedical
Health Equity
Economics
Health Policy
Cost-Benefit Analysis
Public Health, Environmental and Occupational Health
Health Services
Medical and Health Sciences
Good Health and Well Being
Technology Assessment
Clinical Research
Health Policy & Services
Ethnicity
Humans
Generic health relevance
Minority Groups
8.2 Health and welfare economics
Health and social care services research
Subjects
Details
- ISSN :
- 11792027
- Volume :
- 40
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- PharmacoEconomics
- Accession number :
- edsair.doi.dedup.....2f51405862da9c603ed091ef038799aa